Chelamax chelated zinc from Innophos has increased bioavailability to deliver a quality product formulation
Innophos continues to advance research on chelation and its distinct benefits. In this latest webinar, Dr. Bob Finn presents results from our new in vitro digestion studies which show significantly higher absorption of Chelamax® zinc bisglycinate versus traditional zinc oxide. Join us to learn how Chelamax® chelated minerals can offer differentiated performance and proven efficacy and quality.
Key takeaways:
• Chelamax® zinc bisglycinate is 10 times more bioaccessible in the stomach and five times more bioaccessible in intestinal conditions than zinc oxide.
• Chelamax® zinc bisglycinate has an absorption rate that is 10 times greater than zinc oxide.
• The data from our in vitro digestion model suggests the superior bioavailability of Chelamax® zinc bisglycinate over zinc oxide.
Moderator
Heather Granato
VP of Content
Vitafoods - Informa Markets
Speaker
Dr. Robert Finn
Director, Research & Development
Innophos
Dr. Bob Finn is the director of Research, Development and Nutrition at Innophos, Inc. He has 20 years’ experience developing new products in the nutrition, food and industrial markets. During his time at Innophos, he has authored several patents and has over 40 scientific publications. Bob and his team develop new products for key markets including ingredients for food, industrial additives, and nutritional supplements.
Sponsored by: